Scott Thacher

Company: Orphagen Pharmaceuticals

Job title: CEO & Founder

Seminars:

A Novel, Pleiotropic Oral Drug Class that Blocks Gut Migration of Activated T Cells 2:00 pm

• Antagonists to retinoic acid receptor-alpha (RARα) block the upregulation of α4β7 and CCR9 during T cell activation in mesenteric lymph nodes • Daily oral dosing of an RARα antagonist inhibits intestinal epithelial damage in a mouse model of colitis. In separate models, inflammatory T-cell migration to the intestinal lining is also suppressed • Preclinical…Read more

day: Day One